NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free AXGN Stock Alerts $8.07 +0.30 (+3.86%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.74▼$8.1150-Day Range$7.35▼$10.6952-Week Range$3.45▼$10.83Volume172,080 shsAverage Volume431,574 shsMarket Capitalization$348.70 millionP/E RatioN/ADividend YieldN/APrice Target$10.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AxoGen alerts: Email Address AxoGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside32.2% Upside$10.67 Price TargetShort InterestBearish4.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 9 Articles This WeekInsider TradingSelling Shares$928,054 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.46) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector539th out of 938 stocksElectromedical Equipment Industry7th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.67, AxoGen has a forecasted upside of 32.2% from its current price of $8.07.Amount of Analyst CoverageAxoGen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.18% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in AxoGen has recently increased by 21.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 2.4 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for AxoGen this week, compared to 2 articles on an average week.Search Interest11 people have searched for AXGN on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $928,054.00 in company stock.Percentage Held by InsidersOnly 7.21% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.46) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About AxoGen Stock (NASDAQ:AXGN)AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesMarch 26, 2024 | insidertrades.comAxoGen, Inc. (NASDAQ:AXGN) Insider Sells $35,159.04 in StockMarch 26, 2024 | insidertrades.comAxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej Sells 39,280 SharesMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 11, 2024 | insidertrades.comGregory Gene Freitag Sells 25,000 Shares of AxoGen, Inc. (NASDAQ:AXGN) StockMarch 11, 2024 | insidertrades.comAxoGen, Inc. (NASDAQ:AXGN) VP Sells $319,891.10 in StockMarch 26, 2024 | americanbankingnews.comMichael Patrick Donovan Sells 6,033 Shares of AxoGen, Inc. (NASDAQ:AXGN) StockMarch 9, 2024 | finance.yahoo.comDirector Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)March 8, 2024 | finance.yahoo.comUS$13.80 - That's What Analysts Think AxoGen, Inc. (NASDAQ:AXGN) Is Worth After These ResultsMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 7, 2024 | seekingalpha.comAxoGen, Inc. (AXGN) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | markets.businessinsider.comAxogen’s Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price TargetMarch 6, 2024 | sg.finance.yahoo.comAxoGen, Inc. (AXGN) stock price, news, quote & history – Yahoo FinanceMarch 6, 2024 | finanznachrichten.deAxogen, Inc.: Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial ResultsMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed: AxoGen’s Robust Growth and Market Potential Drive Positive OutlookMarch 6, 2024 | msn.comAxoGen files $100M mixed securities shelfMarch 6, 2024 | finance.yahoo.comAxoGen Full Year 2023 Earnings: Beats ExpectationsMarch 6, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | investing.comAxogen Inc (AXGN) Earnings Dates & ReportsMarch 5, 2024 | msn.comAxoGen Non-GAAP EPS of -$0.06 beats by $0.02, revenue of $42.9M beats by $1.9MMarch 5, 2024 | finance.yahoo.comAxogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023March 5, 2024 | globenewswire.comAxogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial ResultsMarch 4, 2024 | msn.comAxoGen Q4 2023 Earnings PreviewFebruary 23, 2024 | ca.finance.yahoo.comAmerican Well Corporation (AMWL)February 22, 2024 | benzinga.comAxogen Stock (NASDAQ:AXGN), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comAXGN Mar 2024 12.500 callFebruary 16, 2024 | finance.yahoo.com3 Best Stocks to Buy for Remarkable Earnings AccelerationFebruary 13, 2024 | finance.yahoo.comAxogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024See More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees426Year FoundedN/APrice Target and Rating Average Stock Price Target$10.67 High Stock Price Target$12.00 Low Stock Price Target$9.00 Potential Upside/Downside+32.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,720,000.00 Net Margins-13.66% Pretax Margin-13.66% Return on Equity-22.38% Return on Assets-11.24% Debt Debt-to-Equity Ratio0.71 Current Ratio2.89 Quick Ratio2.14 Sales & Book Value Annual Sales$159.01 million Price / Sales2.19 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book3.64Miscellaneous Outstanding Shares43,210,000Free Float40,091,000Market Cap$348.70 million OptionableOptionable Beta1.07 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 62)Chairman, President & CEO Comp: $852.18kMr. Michael Donovan (Age 59)Vice President of Operations Comp: $406.02kMr. Angelo G. Scopelianos Ph.D. (Age 68)Chief Research & Development Officer Comp: $540.91kMr. Harold D. TamayoVice President of Finance & Investor RelationsMr. Marc A. Began (Age 56)Executive VP, General Counsel & Chief Compliance Officer Ms. Doris QuackenbushVice President of SalesMr. Jens Schroeder KempChief Marketing OfficerMr. Erick DeVinney (Age 48)Chief Innovation Officer Dr. Ivica Ducic M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsEdap TmsNASDAQ:EDAPZynexNASDAQ:ZYXISemler ScientificNASDAQ:SMLRElectromedNYSE:ELMDFONARNASDAQ:FONRView All CompetitorsInsiders & InstitutionsKaren L ZaderejSold 39,280 sharesTotal: $301,670.40 ($7.68/share)Erick Wayne DevinneySold 4,578 sharesTotal: $35,159.04 ($7.68/share)Michael Patrick DonovanSold 6,033 sharesTotal: $46,333.44 ($7.68/share)Vanguard Group Inc.Sold 13,025 shares on 3/11/2024Ownership: 5.706%Gregory Gene FreitagSold 25,000 sharesTotal: $225,000.00 ($9.00/share)View All Insider TransactionsView All Institutional Transactions AXGN Stock Analysis - Frequently Asked Questions Should I buy or sell AxoGen stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks. What is AxoGen's stock price target for 2024? 3 Wall Street analysts have issued twelve-month price objectives for AxoGen's stock. Their AXGN share price targets range from $9.00 to $12.00. On average, they expect the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts. How have AXGN shares performed in 2024? AxoGen's stock was trading at $6.83 on January 1st, 2024. Since then, AXGN shares have increased by 18.2% and is now trading at $8.07. View the best growth stocks for 2024 here. Are investors shorting AxoGen? AxoGen saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,700,000 shares, an increase of 21.4% from the February 29th total of 1,400,000 shares. Based on an average daily volume of 427,600 shares, the days-to-cover ratio is presently 4.0 days. Approximately 4.2% of the company's shares are short sold. View AxoGen's Short Interest. When is AxoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AXGN earnings forecast. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings results on Tuesday, March, 5th. The medical equipment provider reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.11. The medical equipment provider had revenue of $42.92 million for the quarter, compared to analysts' expectations of $42.70 million. AxoGen had a negative trailing twelve-month return on equity of 22.38% and a negative net margin of 13.66%. What ETF holds AxoGen's stock? iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio. What guidance has AxoGen issued on next quarter's earnings? AxoGen updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $177.0 million-$181.0 million, compared to the consensus revenue estimate of $178.9 million. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL). Who are AxoGen's major shareholders? AxoGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.73%), Vanguard Group Inc. (5.71%), Perceptive Advisors LLC (1.88%), Dimensional Fund Advisors LP (1.35%), Goldman Sachs Group Inc. (1.18%) and Goldman Sachs Group Inc. (1.18%). Insiders that own company stock include Amy Mcbride Wendell, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXGN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.